Global Neisseria meningitidis Infections Drug Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Neisseria meningitidis Infections Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Neisseria meningitidis Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Neisseria meningitidis Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Neisseria meningitidis Infections Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Neisseria meningitidis Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Neisseria meningitidis Infections Drug market include Biological E Ltd, Griffith University, ImmunoBiology Ltd, JN-International Medical Corp, MGB Biopharma Ltd, Panacea Biotec Ltd, Sanofi Pasteur SA, Serum Institute of India Ltd and Wellstat Vaccines LLC, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Neisseria meningitidis Infections Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Neisseria meningitidis Infections Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Neisseria meningitidis Infections Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Neisseria meningitidis Infections Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Neisseria meningitidis Infections Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Neisseria meningitidis Infections Drug sales, projected growth trends, production technology, application and end-user industry.
Neisseria meningitidis Infections Drug Segment by Company
Biological E Ltd
Griffith University
ImmunoBiology Ltd
JN-International Medical Corp
MGB Biopharma Ltd
Panacea Biotec Ltd
Sanofi Pasteur SA
Serum Institute of India Ltd
Wellstat Vaccines LLC
Beijing Minhai Biotechnology Co Ltd
GlaxoSmithKline Plc
China National Pharmaceutical Group Corp
Pfizer Inc
Neisseria meningitidis Infections Drug Segment by Type
TP-10
NCL-195
MGBBP-3
Others
Neisseria meningitidis Infections Drug Segment by Application
Hospital
Clinic
Others
Neisseria meningitidis Infections Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Neisseria meningitidis Infections Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Neisseria meningitidis Infections Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Neisseria meningitidis Infections Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Neisseria meningitidis Infections Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neisseria meningitidis Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neisseria meningitidis Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neisseria meningitidis Infections Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Neisseria meningitidis Infections Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neisseria meningitidis Infections Drug industry.
Chapter 3: Detailed analysis of Neisseria meningitidis Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Neisseria meningitidis Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Neisseria meningitidis Infections Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Neisseria meningitidis Infections Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Neisseria meningitidis Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Neisseria meningitidis Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Neisseria meningitidis Infections Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Neisseria meningitidis Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Neisseria meningitidis Infections Drug market include Biological E Ltd, Griffith University, ImmunoBiology Ltd, JN-International Medical Corp, MGB Biopharma Ltd, Panacea Biotec Ltd, Sanofi Pasteur SA, Serum Institute of India Ltd and Wellstat Vaccines LLC, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Neisseria meningitidis Infections Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Neisseria meningitidis Infections Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Neisseria meningitidis Infections Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Neisseria meningitidis Infections Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Neisseria meningitidis Infections Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Neisseria meningitidis Infections Drug sales, projected growth trends, production technology, application and end-user industry.
Neisseria meningitidis Infections Drug Segment by Company
Biological E Ltd
Griffith University
ImmunoBiology Ltd
JN-International Medical Corp
MGB Biopharma Ltd
Panacea Biotec Ltd
Sanofi Pasteur SA
Serum Institute of India Ltd
Wellstat Vaccines LLC
Beijing Minhai Biotechnology Co Ltd
GlaxoSmithKline Plc
China National Pharmaceutical Group Corp
Pfizer Inc
Neisseria meningitidis Infections Drug Segment by Type
TP-10
NCL-195
MGBBP-3
Others
Neisseria meningitidis Infections Drug Segment by Application
Hospital
Clinic
Others
Neisseria meningitidis Infections Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Neisseria meningitidis Infections Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Neisseria meningitidis Infections Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Neisseria meningitidis Infections Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Neisseria meningitidis Infections Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neisseria meningitidis Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neisseria meningitidis Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neisseria meningitidis Infections Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Neisseria meningitidis Infections Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neisseria meningitidis Infections Drug industry.
Chapter 3: Detailed analysis of Neisseria meningitidis Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Neisseria meningitidis Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Neisseria meningitidis Infections Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
192 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Neisseria meningitidis Infections Drug Sales Value (2020-2031)
- 1.2.2 Global Neisseria meningitidis Infections Drug Sales Volume (2020-2031)
- 1.2.3 Global Neisseria meningitidis Infections Drug Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Neisseria meningitidis Infections Drug Market Dynamics
- 2.1 Neisseria meningitidis Infections Drug Industry Trends
- 2.2 Neisseria meningitidis Infections Drug Industry Drivers
- 2.3 Neisseria meningitidis Infections Drug Industry Opportunities and Challenges
- 2.4 Neisseria meningitidis Infections Drug Industry Restraints
- 3 Neisseria meningitidis Infections Drug Market by Company
- 3.1 Global Neisseria meningitidis Infections Drug Company Revenue Ranking in 2024
- 3.2 Global Neisseria meningitidis Infections Drug Revenue by Company (2020-2025)
- 3.3 Global Neisseria meningitidis Infections Drug Sales Volume by Company (2020-2025)
- 3.4 Global Neisseria meningitidis Infections Drug Average Price by Company (2020-2025)
- 3.5 Global Neisseria meningitidis Infections Drug Company Ranking (2023-2025)
- 3.6 Global Neisseria meningitidis Infections Drug Company Manufacturing Base and Headquarters
- 3.7 Global Neisseria meningitidis Infections Drug Company Product Type and Application
- 3.8 Global Neisseria meningitidis Infections Drug Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Neisseria meningitidis Infections Drug Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Neisseria meningitidis Infections Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Neisseria meningitidis Infections Drug Market by Type
- 4.1 Neisseria meningitidis Infections Drug Type Introduction
- 4.1.1 TP-10
- 4.1.2 NCL-195
- 4.1.3 MGBBP-3
- 4.1.4 Others
- 4.2 Global Neisseria meningitidis Infections Drug Sales Volume by Type
- 4.2.1 Global Neisseria meningitidis Infections Drug Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Neisseria meningitidis Infections Drug Sales Volume by Type (2020-2031)
- 4.2.3 Global Neisseria meningitidis Infections Drug Sales Volume Share by Type (2020-2031)
- 4.3 Global Neisseria meningitidis Infections Drug Sales Value by Type
- 4.3.1 Global Neisseria meningitidis Infections Drug Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Neisseria meningitidis Infections Drug Sales Value by Type (2020-2031)
- 4.3.3 Global Neisseria meningitidis Infections Drug Sales Value Share by Type (2020-2031)
- 5 Neisseria meningitidis Infections Drug Market by Application
- 5.1 Neisseria meningitidis Infections Drug Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Neisseria meningitidis Infections Drug Sales Volume by Application
- 5.2.1 Global Neisseria meningitidis Infections Drug Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Neisseria meningitidis Infections Drug Sales Volume by Application (2020-2031)
- 5.2.3 Global Neisseria meningitidis Infections Drug Sales Volume Share by Application (2020-2031)
- 5.3 Global Neisseria meningitidis Infections Drug Sales Value by Application
- 5.3.1 Global Neisseria meningitidis Infections Drug Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Neisseria meningitidis Infections Drug Sales Value by Application (2020-2031)
- 5.3.3 Global Neisseria meningitidis Infections Drug Sales Value Share by Application (2020-2031)
- 6 Neisseria meningitidis Infections Drug Regional Sales and Value Analysis
- 6.1 Global Neisseria meningitidis Infections Drug Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Neisseria meningitidis Infections Drug Sales by Region (2020-2031)
- 6.2.1 Global Neisseria meningitidis Infections Drug Sales by Region: 2020-2025
- 6.2.2 Global Neisseria meningitidis Infections Drug Sales by Region (2026-2031)
- 6.3 Global Neisseria meningitidis Infections Drug Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Neisseria meningitidis Infections Drug Sales Value by Region (2020-2031)
- 6.4.1 Global Neisseria meningitidis Infections Drug Sales Value by Region: 2020-2025
- 6.4.2 Global Neisseria meningitidis Infections Drug Sales Value by Region (2026-2031)
- 6.5 Global Neisseria meningitidis Infections Drug Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Neisseria meningitidis Infections Drug Sales Value (2020-2031)
- 6.6.2 North America Neisseria meningitidis Infections Drug Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Neisseria meningitidis Infections Drug Sales Value (2020-2031)
- 6.7.2 Europe Neisseria meningitidis Infections Drug Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Neisseria meningitidis Infections Drug Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Neisseria meningitidis Infections Drug Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Neisseria meningitidis Infections Drug Sales Value (2020-2031)
- 6.9.2 South America Neisseria meningitidis Infections Drug Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Neisseria meningitidis Infections Drug Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Neisseria meningitidis Infections Drug Sales Value Share by Country, 2024 VS 2031
- 7 Neisseria meningitidis Infections Drug Country-level Sales and Value Analysis
- 7.1 Global Neisseria meningitidis Infections Drug Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Neisseria meningitidis Infections Drug Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Neisseria meningitidis Infections Drug Sales by Country (2020-2031)
- 7.3.1 Global Neisseria meningitidis Infections Drug Sales by Country (2020-2025)
- 7.3.2 Global Neisseria meningitidis Infections Drug Sales by Country (2026-2031)
- 7.4 Global Neisseria meningitidis Infections Drug Sales Value by Country (2020-2031)
- 7.4.1 Global Neisseria meningitidis Infections Drug Sales Value by Country (2020-2025)
- 7.4.2 Global Neisseria meningitidis Infections Drug Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.9.2 France Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.16.2 China Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.19.2 India Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Neisseria meningitidis Infections Drug Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Neisseria meningitidis Infections Drug Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Neisseria meningitidis Infections Drug Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Biological E Ltd
- 8.1.1 Biological E Ltd Comapny Information
- 8.1.2 Biological E Ltd Business Overview
- 8.1.3 Biological E Ltd Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Biological E Ltd Neisseria meningitidis Infections Drug Product Portfolio
- 8.1.5 Biological E Ltd Recent Developments
- 8.2 Griffith University
- 8.2.1 Griffith University Comapny Information
- 8.2.2 Griffith University Business Overview
- 8.2.3 Griffith University Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Griffith University Neisseria meningitidis Infections Drug Product Portfolio
- 8.2.5 Griffith University Recent Developments
- 8.3 ImmunoBiology Ltd
- 8.3.1 ImmunoBiology Ltd Comapny Information
- 8.3.2 ImmunoBiology Ltd Business Overview
- 8.3.3 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2020-2025)
- 8.3.4 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Product Portfolio
- 8.3.5 ImmunoBiology Ltd Recent Developments
- 8.4 JN-International Medical Corp
- 8.4.1 JN-International Medical Corp Comapny Information
- 8.4.2 JN-International Medical Corp Business Overview
- 8.4.3 JN-International Medical Corp Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2020-2025)
- 8.4.4 JN-International Medical Corp Neisseria meningitidis Infections Drug Product Portfolio
- 8.4.5 JN-International Medical Corp Recent Developments
- 8.5 MGB Biopharma Ltd
- 8.5.1 MGB Biopharma Ltd Comapny Information
- 8.5.2 MGB Biopharma Ltd Business Overview
- 8.5.3 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2020-2025)
- 8.5.4 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Product Portfolio
- 8.5.5 MGB Biopharma Ltd Recent Developments
- 8.6 Panacea Biotec Ltd
- 8.6.1 Panacea Biotec Ltd Comapny Information
- 8.6.2 Panacea Biotec Ltd Business Overview
- 8.6.3 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Product Portfolio
- 8.6.5 Panacea Biotec Ltd Recent Developments
- 8.7 Sanofi Pasteur SA
- 8.7.1 Sanofi Pasteur SA Comapny Information
- 8.7.2 Sanofi Pasteur SA Business Overview
- 8.7.3 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Product Portfolio
- 8.7.5 Sanofi Pasteur SA Recent Developments
- 8.8 Serum Institute of India Ltd
- 8.8.1 Serum Institute of India Ltd Comapny Information
- 8.8.2 Serum Institute of India Ltd Business Overview
- 8.8.3 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Product Portfolio
- 8.8.5 Serum Institute of India Ltd Recent Developments
- 8.9 Wellstat Vaccines LLC
- 8.9.1 Wellstat Vaccines LLC Comapny Information
- 8.9.2 Wellstat Vaccines LLC Business Overview
- 8.9.3 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Product Portfolio
- 8.9.5 Wellstat Vaccines LLC Recent Developments
- 8.10 Beijing Minhai Biotechnology Co Ltd
- 8.10.1 Beijing Minhai Biotechnology Co Ltd Comapny Information
- 8.10.2 Beijing Minhai Biotechnology Co Ltd Business Overview
- 8.10.3 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Product Portfolio
- 8.10.5 Beijing Minhai Biotechnology Co Ltd Recent Developments
- 8.11 GlaxoSmithKline Plc
- 8.11.1 GlaxoSmithKline Plc Comapny Information
- 8.11.2 GlaxoSmithKline Plc Business Overview
- 8.11.3 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2020-2025)
- 8.11.4 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Product Portfolio
- 8.11.5 GlaxoSmithKline Plc Recent Developments
- 8.12 China National Pharmaceutical Group Corp
- 8.12.1 China National Pharmaceutical Group Corp Comapny Information
- 8.12.2 China National Pharmaceutical Group Corp Business Overview
- 8.12.3 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2020-2025)
- 8.12.4 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Product Portfolio
- 8.12.5 China National Pharmaceutical Group Corp Recent Developments
- 8.13 Pfizer Inc
- 8.13.1 Pfizer Inc Comapny Information
- 8.13.2 Pfizer Inc Business Overview
- 8.13.3 Pfizer Inc Neisseria meningitidis Infections Drug Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Pfizer Inc Neisseria meningitidis Infections Drug Product Portfolio
- 8.13.5 Pfizer Inc Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Neisseria meningitidis Infections Drug Value Chain Analysis
- 9.1.1 Neisseria meningitidis Infections Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Neisseria meningitidis Infections Drug Sales Mode & Process
- 9.2 Neisseria meningitidis Infections Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Neisseria meningitidis Infections Drug Distributors
- 9.2.3 Neisseria meningitidis Infections Drug Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.



